Ownership Capital B.V. Sells 132,832 Shares of Zoetis Inc. (NYSE:ZTS)

Ownership Capital B.V. trimmed its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 15.6% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 716,146 shares of the company's stock after selling 132,832 shares during the period. Zoetis accounts for about 5.4% of Ownership Capital B.V.'s investment portfolio, making the stock its 7th biggest holding. Ownership Capital B.V. owned about 0.16% of Zoetis worth $117,913,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Rakuten Securities Inc. lifted its holdings in Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after acquiring an additional 166 shares during the last quarter. Navigoe LLC bought a new position in Zoetis in the fourth quarter worth about $30,000. Cornerstone Planning Group LLC lifted its holdings in Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after acquiring an additional 88 shares during the last quarter. Murphy & Mullick Capital Management Corp bought a new position in Zoetis in the fourth quarter worth about $44,000. Finally, Sound Income Strategies LLC lifted its holdings in Zoetis by 141.4% in the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock worth $46,000 after acquiring an additional 164 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the transaction, the executive vice president directly owned 15,129 shares in the company, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.18% of the company's stock.

Analysts Set New Price Targets

ZTS has been the topic of a number of recent research reports. Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and cut their target price for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. UBS Group cut their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Finally, Piper Sandler raised their target price on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Monday, May 12th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Zoetis presently has an average rating of "Buy" and an average target price of $212.13.

Zoetis Stock Performance

Zoetis stock traded down $3.89 during mid-day trading on Friday, hitting $154.91. 2,267,443 shares of the company's stock traded hands, compared to its average volume of 2,591,359. The firm has a 50 day moving average price of $161.32 and a 200 day moving average price of $161.86. The company has a quick ratio of 1.04, a current ratio of 1.74 and a debt-to-equity ratio of 1.12. The company has a market cap of $68.97 billion, a PE ratio of 27.81, a price-to-earnings-growth ratio of 2.63 and a beta of 0.91. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The company had revenue of $2.22 billion for the quarter, compared to analysts' expectations of $2.20 billion. During the same period last year, the firm earned $1.38 EPS. The firm's revenue for the quarter was up 1.4% on a year-over-year basis. On average, equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.29%. The ex-dividend date is Friday, July 18th. Zoetis's dividend payout ratio (DPR) is presently 35.91%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.